Experion Receives License to Sell Cannabis Flower to Medical Patients
October 17, 2018 (Source) — Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR) (OTC PINK: VIRFF) is pleased to announce that its wholly owned subsidiary, Experion Biotechnologies Inc. (“Experion”), has received an amended license from Health Canada allowing for the sale of dried flower directly to customers holding a valid medical prescription. This amended license permits Experion to register medical patients as customers, process purchase orders, and ship to patients directly.
Approval of direct sale to patients now completes and rounds out the portfolio of sales license amendments held by Experion for the Canadian medical market. Experion may now sell starter material and dried flower to both wholesale and end customers nationally across Canada. By achieving the final sales license, the company will transition to several new licenses under the Cannabis Act with the same capabilities taking effect on October 17, 2018. Experion anticipates launching its e-marketplace for medical patients in December 2018 through its website, www.expbiotech.com.
Mr. Jay Garnett, Chief Executive Officer of Viridium, commented, “With approval for sale to medical patients, Experion is now open for business to every kind of medical cannabis buyer in Canada. We’re very proud of our team in Mission who have gone above and beyond in this last licensing push. This amendment represents the culmination of all of our work over the past 14 months since receiving our LP.”
Viridium Pacific Group Ltd. is a consumer wellness and biotech innovation company based in British Columbia, and the parent company of operating subsidiaries involved in horticultural production, (Experion Biotechologies Inc.) property development (Fish Trap Ventures Ltd.), and human resource management (Stave Lake Services Ltd.) Experion Biotechnologies Inc., is a Health Canada licensed producer of cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission, BC.
More information about Viridium can be found under the Company’s profile on SEDAR at www.sedar.com.
This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.
Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.
Get our daily investorintel update
InvestorIntel is a trusted source of reliable information at the forefront of emerging markets that brings investment opportunities to discerning investors.